VIrtual Reality Glasses Use to Improve Lateropulsion and the Post-stroke Postural Vertical
Launched by UNIVERSITY HOSPITAL, GRENOBLE · May 27, 2021
Trial Information
Current as of May 06, 2025
Recruiting
Keywords
ClinConnect Summary
The VIRGIL clinical trial is exploring how using virtual reality glasses in a tilted room can help improve balance and body orientation in people who have had a stroke. The study aims to see if this new approach can assist in correcting a common problem called "lateropulsion," which is when people have difficulty sensing their body's vertical position after a stroke. The trial will include both stroke survivors and healthy individuals to better understand the effects of this technology.
To participate, stroke patients need to be hospitalized in neurorehabilitation, have experienced a stroke within the last six months, and show signs of lateropulsion. Healthy participants are also welcome, but they should not have any history of neurological issues or balance disorders. Participants can expect to spend time in a virtual reality setting, where their responses and improvements will be carefully monitored. This study is currently recruiting, and it's important for interested individuals to check the eligibility criteria to see if they qualify.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 20 stroke participants
- • Hospitalized in neurorehabilitation
- • Hemisphere stroke (Right or left)
- • Stroke delay \< 6 months
- • Presence of lateropulsion assessed by the Scale for Contraversive Pushing (SCP) \> 0.5
- • 20 healthy participants
- • No history of stroke or others neurological pathologies
- • No balance disorders
- • No history of vestibular or dizzissness disorders
- Exclusion Criteria:
- • All
- • History of psychiatric disorders
- • Nyctophobia
- • Advanced heart failure
- • Severe trunk deformation with C7 lateral \> 30 mm due to a independant cause beyond the stroke (i.e., scoliosis) or history of postural disorder
- • 20 Stroke participants
- • Medical instability making the assessment impossible
- • Comprehension deficits with Boston Diagnostic Aphasia Examination gravity score ≥3
- • History of vestibular or dizzissness disorders
- • No previous neurological history interfering with balance
- • Inability to understand and execute simple orders
- • Severe untreated depression (Aphasic Depression Rating Scale (ADRS) score \>15)
About University Hospital, Grenoble
The University Hospital of Grenoble is a leading academic medical center dedicated to advancing healthcare through innovative clinical research and comprehensive patient care. As a prominent sponsor of clinical trials, the hospital leverages its expertise in various medical disciplines to facilitate cutting-edge studies that aim to improve treatment outcomes and enhance patient safety. With a strong commitment to collaboration, the University Hospital of Grenoble engages in partnerships with academic institutions, industry leaders, and regulatory bodies to drive scientific discovery and translate research findings into clinical practice. Its state-of-the-art facilities and multidisciplinary teams ensure rigorous adherence to ethical standards and regulatory guidelines, fostering an environment where groundbreaking research can thrive.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Grenoble, , France
Patients applied
Trial Officials
Dominic Pérennou
Principal Investigator
University Hospital, Grenoble
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials